Determination of species and instars of the larvae of the Afrotropical species of Thanatophilus Leach, 1817 (Coleoptera, Silphidae)

Thanatophilus micans and T. mutilatus have significance for forensic entomology. Their larvae are therefore described and a key is provided for identifying the larvae of Afrotropical Silphidae based on morphological characters. It is shown that seven common species of Thanatophilus can be distinguished by a 360 bp mtDNA sequence from the cytochrome oxidase I gene

Corrigenda: Daniel CA, Midgley JM, Villet MH (2017) Determination of species and instars of the larvae of the Afrotropical species of Thanatophilus Leach, 1817 (Coleoptera, Silphidae). African Invertebrates 58(2): 1-10. https://doi.org/10.3897/afrinvertebr.58.12966

After the publication of this article, it was brought to our attention that there was an error in the caption for Figure 2. The caption should read: Figure 2: Right mandible in dorsal view and mesothoracic spiracle of mature Afrotropical Thanatophilus larvae. The arrows indicate species-specific diagnostic characteristics: T. micans has two ventrolateral mandibular setae and two spiracular setae, while T. mutilatus has three ventrolateral mandibular setae and one spiracular seta

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer

Background Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. Methods All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indicated. The trial was terminated prematurely owing to worldwide withdrawal of rofecoxib. To examine possible persistent risks, we examined cardiovascular thrombotic events reported up to 24 months after the trial was closed. Results The median duration of active treatment was 7.4 months. The 1167 patients receiving rofecoxib and the 1160 patients receiving placebo were well matched, with a median follow-up period of 33.0 months (interquartile range, 27.6 to 40.1) and 33.4 months (27.7 to 40.4), respectively. Of the 23 confirmed cardiovascular thrombotic events, 16 occurred in the rofecoxib group during or within 14 days after the treatment period, with an estimated relative risk of 2.66 (from the Cox proportional-hazards model; 95% confidence interval [CI], 1.03 to 6.86; P = 0.04). Analysis of the Antiplatelet Trialists’ Collaboration end point (the combined incidence of death from cardiovascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of 1.60 (95% CI, 0.57 to 4.51; P = 0.37). Fourteen more cardiovascular thrombotic events, six in the rofecoxib group, were reported within the 2 years after trial closure, with an overall unadjusted relative risk of 1.50 (95% CI, 0.76 to 2.94; P = 0.24). Four patients in the rofecoxib group and two in the placebo group died from thrombotic causes during or within 14 days after the treatment period, and during the follow-up period, one patient in the rofecoxib group and five patients in the placebo group died from cardiovascular causes. Conclusions Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months’ duration. (Current Controlled Trials number, ISRCTN98278138.

Early biological markers of post-acute sequelae of SARS-CoV-2 infection.

To understand the roles of acute-phase viral dynamics and host immune responses in post-acute sequelae of SARS-CoV-2 infection (PASC), we enrolled 136 participants within 5 days of their first positive SARS-CoV-2 real-time PCR test. Participants self-collected up to 21 nasal specimens within the first 28 days post-symptom onset; interviewer-administered questionnaires and blood samples were collected at enrollment, days 9, 14, 21, 28, and month 4 and 8 post-symptom onset. Defining PASC as the presence of any COVID-associated symptom at their 4-month visit, we compared viral markers (quantity and duration of nasal viral RNA load, infectious viral load, and plasma N-antigen level) and host immune markers (IL-6, IL-10, TNF-α, IFN-α, IFN-γ, MCP, IP-10, and Spike IgG) over the acute period. Compared to those who fully recovered, those reporting PASC demonstrated significantly higher maximum levels of SARS-CoV-2 RNA and N-antigen, burden of RNA and infectious viral shedding, and lower Spike-specific IgG levels within 9 days post-illness onset. No significant differences were identified among a panel of host immune markers. Our results suggest early viral dynamics and the associated host immune responses play a role in the pathogenesis of PASC, highlighting the importance of understanding early biological markers in the natural history of PASC

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk

We performed a meta-analysis of five genome-wide association studies to identify common variants influencing colorectal cancer (CRC) risk comprising 8,682 cases and 9,649 controls. Replication analysis was performed in case-control sets totaling 21,096 cases and 19,555 controls. We identified three new CRC risk loci at 6p21 (rs1321311, near CDKN1A; P = 1.14 × 10(-10)), 11q13.4 (rs3824999, intronic to POLD3; P = 3.65 × 10(-10)) and Xp22.2 (rs5934683, near SHROOM2; P = 7.30 × 10(-10)) This brings the number of independent loci associated with CRC risk to 20 and provides further insight into the genetic architecture of inherited susceptibility to CRC.Swedish Research Council et al.Manuscrip

Treatments for people who use anabolic androgenic steroids: a scoping review.

BACKGROUND: A growing body of evidence suggests that anabolic androgenic steroids (AAS) are used globally by a diverse population with varying motivations. Evidence has increased greatly in recent years to support understanding of this form of substance use and the associated health harms, but there remains little evidence regarding interventions to support cessation and treat the consequences of use. In this scoping review, we identify and describe what is known about interventions that aim to support and achieve cessation of AAS, and treat and prevent associated health problems. METHODS: A comprehensive search strategy was developed in four bibliographic databases, supported by an iterative citation searching process to identify eligible studies. Studies of any psychological or medical treatment interventions delivered in response to non-prescribed use of AAS or an associated harm in any setting were eligible. RESULTS: In total, 109 eligible studies were identified, which included case reports representing a diverse range of disciplines and sources. Studies predominantly focussed on treatments for harms associated with AAS use, with scant evidence on interventions to support cessation of AAS use or responding to dependence. The types of conditions requiring treatment included psychiatric, neuroendocrine, hepatic, kidney, cardiovascular, musculoskeletal and infectious. There was limited evidence of engagement with users or delivery of psychosocial interventions as part of treatment for any condition, and of harm reduction interventions initiated alongside, or following, treatment. Findings were limited throughout by the case report study designs and limited information was provided. CONCLUSION: This scoping review indicates that while a range of case reports describe treatments provided to AAS users, there is scarce evidence on treating dependence, managing withdrawal, or initiating behaviour change in users in any settings. Evidence is urgently required to support the development of effective services for users and of evidence-based guidance and interventions to respond to users in a range of healthcare settings. More consistent reporting in articles of whether engagement or assessment relating to AAS was initiated, and publication within broader health- or drug-related journals, will support development of the evidence base

When Every Day is a High School Reunion: Social Media Comparisons and Self-esteem

Although past research has shown that social comparisons made through social media contribute to negative outcomes, little is known about the nature of these comparisons (e.g., domains, direction, and extremity), variables that determine the outcomes of these comparisons (e.g., post valence, perceiver’s self-esteem), and how these comparisons differ from those made in other contexts (e.g. while texting or interacting face to face). In five studies (N=900), I provide the first comprehensive analysis of how individuals make and respond to social comparisons on two different social media platforms (Facebook and Instagram), using comparisons made in real-time while participants browsed their own social media news feeds (Studies 1 and 3), experimenter-generated social media content (Study 2), and reports of comparisons made in various contexts, including social media (Studies 4 and 5). I found that individuals made frequent upward comparisons on social media. Further, social media comparisons were more likely to be upward than downward, and making more frequent and more extreme upward comparisons on social media resulted in greater declines in self-evaluations, mood, and life satisfaction. In addition, individuals with lower self-esteem made more frequent and extreme upward comparisons while browsing social media, resulting in even steeper declines in self-evaluations. Finally, compared to upward comparisons in other contexts, those made on social media were more often to distant (vs. close) targets, more likely to be image-based, and resulted in greater declines in self-evaluations. Together, these studies provide the first insights into the cumulative impact of multiple social comparisons, demonstrate the unique nature of social comparisons made on social media, and clarify the role of self-esteem in online social comparison processes.Ph.D

Keeping in Touch or Keeping Score? Social Comparisons on Facebook

In face-to-face contexts, individuals typically make one social comparison per day and make more self-enhancing downward comparisons (to worse-off others) than potentially threatening upward comparisons (to better-off others). However, online social networks such as Facebook may be radically altering these standards. In two studies, I examined the frequency, direction, and impact of social comparisons on Facebook, and investigated potential moderating factors, including self-esteem. Participants reported making more upward than downward Facebook comparisons (Studies 1 and 2) and made an average of four comparisons in a 20-minute Facebook session (Study 2). Both low self-esteem and being motivated to log onto Facebook to get information with others predict making more comparisons on Facebook (Study 1) and participants with lower self-esteem may feel worse about themselves after making both upward and downward Facebook comparisons compared to their higher self-esteem peers (Study 2).MAS